ArticleInternational urology and nephrology2015
Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis.
Article in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Neutrophil-Mimetic Nanoscavengers Target the Inflammatory Microenvironment to Eliminate NETs/ROS and Immunomodulate cGAS-STING Signaling in Septic AKI.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nephroprotective Effect of L-Carvone on a Mouse Model of LPS-Induced Sepsis-Associated Renal Injury via Regulation of TLR4/NF-κB/AP-1/IRF-3 and Nrf2/iNOS Molecular Signaling Cascades.Journal of Taibah University Medical Sciences · 2026Article
- Edaravone mitigates calcium oxalate-induced renal tubular epithelial cell injury by inhibiting autophagy-mediated ferroptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Beneficial Effects of Butyrate on Kidney Disease.Nutrients · 2025Review
- Evolving of treatment options for cerebral infarction.World journal of clinical cases · 2024Article
- Sorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3/MLKL pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Edaravone-loaded poly(amino acid) nanogel inhibits ferroptosis for neuroprotection in cerebral ischemia injury.Asian journal of pharmaceutical sciences · 2024Article
- The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model.Journal of cardiovascular and thoracic research · 2024Article
- Natural ursolic acid based self-therapeutic polymer as nanocarrier to deliver natural resveratrol for natural therapy of acute kidney injury.Journal of nanobiotechnology · 2023Article
- Protective Effect of Silymarin on Liver in Experimental in the Sepsis Model of Rats.Acta histochemica et cytochemica · 2023Article
- Hydrogenated Germanene Nanosheets as an Antioxidative Defense Agent for Acute Kidney Injury Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Renal safety evaluation of aspirin plus edaravone in patients with ischaemic stroke: a retrospective cohort study.BMJ open · 2022Article
- Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection.Antioxidants (Basel, Switzerland) · 2022Review
- Redox-Mediated Artificial Non-Enzymatic Antioxidant MXene Nanoplatforms for Acute Kidney Injury Alleviation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The Protective Effects of Perindopril Against Acute Kidney Damage Caused by Septic Shock.Inflammation · 2021Article
- Clinically translatable gold nanozymes with broad spectrum antioxidant and anti-inflammatory activity for alleviating acute kidney injury.Theranostics · 2021Article
- Article
- Neuronal Mitochondria Modulation of LPS-Induced Neuroinflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice.Nature communications · 2018Article
- Kidney disease models: tools to identify mechanisms and potential therapeutic targets.Zoological research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute kidney injury (AKI) is a frequent complication of sepsis. The present work examined the therapeutic potential of edaravone (EDA), a free radical scavenger, for inhibiting sepsis-induced renal injury.
methodsSaline and lipopolysaccharide (LPS) were injected intraperitoneally at a dose of 10 mg/kg of body weight. EDA, 3-methyl-1-phenyl-pyrazolin-5-one, was administrated intravenously at a dose of 3 mg/kg of body weight to male Wistar rats. Wistar rats were divided into four groups: treatment with LPS alone, treatment with LPS followed by EDA administration, treatment with saline followed by EDA administration, and untreated controls.
resultsAdministration of LPS caused a significant increase in BUN and serum creatinine levels with concurrent pathological alterations in kidney tissues. EDA treatment relieved all these changes. Moreover, EDA reduced LPS-induced elevation of serum TNF-α and IL-6 in rats. Furthermore, EDA could prevent mitochondrial membrane potential loss induced by LPS and reverse the changes in mitochondrial antioxidant (such as T-AOC, SOD, CAT, and GSH) and mitochondrial MDA levels. TUNEL staining of the kidney sections and immunoblot analysis on renal cortical lysates showed that EDA treatment resulted in reduced number of apoptotic cells, which occurred concomitantly with decreased levels of cytochrome c and cleaved caspase 3. Following LPS treatment of rat renal tubular cells, mitochondrial fragmentation was observed prior to apoptosis, which was inhibited by EDA.
conclusionsEDA prevents LPS-induced AKI not only by reducing the production of inflammatory cytokines, but also by attenuating oxidative damage in renal mitochondria, mitochondrial fragmentation, and apoptosis of renal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.